Drugs / AZD8529
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00985933 | Feb 2010 → Apr 2011 | cognitive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT00986531 | Nov 2009 → Oct 2011 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00886756 | Apr → Jul 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00765492 | Oct 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00755378 | Sep 2008 → Mar 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00921804 | Jun 2009 → May 2010 | schizophrenia | AstraZeneca | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02401022 Comparator | Jul 2015 → Nov 2016 | nicotine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8529 | “The purpose of this study is to determine whether treatment with daily oral dose of AZD8529 40 mg administered over 28 days is safe, well tolerated and improves main symptoms...” NCT00921804 ↗ |
| Modality | Other / unclassified | “mGluR2/3 Positive Allosteric Modulator” NCT00985933 ↗ |
| Route | Oral | “Oral” NCT00755378 ↗ |